نتایج جستجو برای: hypercvad

تعداد نتایج: 72  

Journal: :Blood 2015
Yves Chalandon Xavier Thomas Sandrine Hayette Jean-Michel Cayuela Claire Abbal Françoise Huguet Emmanuel Raffoux Thibaut Leguay Philippe Rousselot Stéphane Lepretre Martine Escoffre-Barbe Sébastien Maury Céline Berthon Emmanuelle Tavernier Jean-François Lambert Marina Lafage-Pochitaloff Véronique Lhéritier Sylvie Chevret Norbert Ifrah Hervé Dombret

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) in 268 adults (median age, 47 years) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The primary objective was the majo...

2016
Xiaorong Ma Yan Xu Wanggang Zhang Jin Wang Xingmei Cao Yinxia Chen Aili He Jie Liu Jianli Wang Wanhong Zhao Yun Yang

BACKGROUND Patients <60 years old with high-risk diffuse large B-cell lymphoma (DLBCL) receiving standard RCHOP(E) treatment display high relapse rates. Here, we compared this standard regimen to a high-intensity regimen in terms of recurrence and long-term survival. MATERIAL AND METHODS Newly diagnosed DLBCL patients <60 years old who were treated at the Second Hospital Affiliated with Xi'an J...

2009
Deborah A. Thomas Susan O’Brien Jeffrey L. Jorgensen Jorge Cortes Stefan Faderl Guillermo Garcia-Manero Srdan Verstovsek Charles Koller Sherry Pierce Yang Huh William Wierda Michael J. Keating Hagop M. Kantarjian

Immunophenotypic classification of acute lymphoblastic leukemia (ALL) has well-recognized prognostic implications. The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results. We retrospectively analyzed the influence of CD20 expression on outcome in 253 adults with de novo precursor B-lineage ALL treated with either conventional (VAD/CVA...

2016
Wilfred Delacruz Robert Setlik Arash Hassantoufighi Shyam Daya Susannah Cooper Dale Selby Alexander Brown

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The fi...

2007
Margaret A. Shipp Thomas M. Habermann

The aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید